SlideShare is now on Android. 15 million presentations at your fingertips.  Get the app

×
  • Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
 

Product profiles alzheimer's disease immunotherapies can revolutionize treatment paradigm

by on Nov 14, 2011

  • 870 views

The beta-amyloid hypothesis has so far failed to deliver a viable candidate, contributing to an absence of new market entrants over the past decade. However, given the weight of candidates with ...

The beta-amyloid hypothesis has so far failed to deliver a viable candidate, contributing to an absence of new market entrants over the past decade. However, given the weight of candidates with disease-modifying potential in the pipeline, new drugs are expected to emerge that will satisfy one of the biggest unmet needs in the industry – a treatment that slows Alzheimer’s disease neurodegeneration.Market Research Reports, Market Research, Industry Analysis, Market Share, Market Size, marketing research,
Pharmaceutical Market Research,Pharmaceutical Market Research Reports,Pharmaceuticals Market Research,Pharmaceuticals Market Research Reports

Statistics

Views

Total Views
870
Views on SlideShare
870
Embed Views
0

Actions

Likes
0
Downloads
5
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via SlideShare as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
Post Comment
Edit your comment

Product profiles alzheimer's disease   immunotherapies can revolutionize treatment paradigm Product profiles alzheimer's disease immunotherapies can revolutionize treatment paradigm Document Transcript